Biotech | September 03, 2021
DGCI green lights Biological E for Phase 2/3 trials of its Covid-19 vaccine candidate for children
The trial will be conducted across 10 sites in India
The trial will be conducted across 10 sites in India
The vaccine is designed to neutralise the virus in the nostril itself and prevent it from penetrating deep down into the respiratory tract
The value of the contract is estimated to be between Rs 20-30 crores per year for the next three years
The segment delivered strong sales growth of 20% YoY
The Visby Medical sexual health click test is the first instrument-free PCR test for the detection of chlamydia, gonorrhoea and trichomonas, with results available within 30 minutes, during the patient visit
Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options
The investment will establish drug product manufacturing capacity for clinical trial and commercial supply in China and offer customers combined drug substance and drug product manufacturing services
The agreement is to develop, manufacture and commercialise biosimilars for the global market.
The aim is to give a fillip to R&D in the health sector to face the Covid-19 challenge
Viraleze was developed for application in the nasal cavity to help reduce exposure to respiratory viruses, including SARS-CoV-2. The product is registered for sale in Europe and India, and available online in certain markets
Subscribe To Our Newsletter & Stay Updated
